Whole-body PBPK model of erythromycin as CYP3A4 perpetrator drug
This repository contains:
- a PK-Sim snapshot (*.json) file of the current PBPK model
- static content (e.g. text blocks, *.md files) as inputs for an evaluation plan
- an evaluation plan (evaluation-plan.json) to create an evaluation report using the snapshot and static text blocks to display the performance of the model
The latest release of the snapshot of the model, the evaluation plan and the static content can be found here.
The latest release of the PK-Sim project model file and the respective evaluation report can be found here.
This erythromycin model is intended to be used in the context of CYP3A4-mediated drug-drug interactions.
The model features metabolism by CYP3A4, glomerular filtration, and a dummy clearance (technically implemented as hepatic plasma clearance) that accounts for additional clearance pathways, as well as mechanism-based inhibition of CYP3A4. The model has been developed using a broad range of clinical data reported in the literature for the following salt forms and formulation types:
- erythromycin lactobionate for intravenous (IV) administration
- erythromycin stearate in film-coated tablets for oral (PO) administration
- erythromycin as free base in enteric-coated tablets for oral (PO) administration
- erythromycin as free base in enteric-coated capsules containing pellets for oral (PO) administration
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.
The model code is distributed under the GPLv2 License.